CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3600
-0.0700 (-2.88%)
As of 11:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.4300
Open2.4500
Bid2.3800 x 900
Ask2.3900 x 2200
Day's Range2.3400 - 2.4500
52 Week Range2.0100 - 11.5500
Volume99,226
Avg. Volume208,642
Market Cap35.444M
Beta (3Y Monthly)4.20
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call

    Celldex Therapeutics, Inc. (CLDX) will report second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2019 financial results and to provide an update on key research and development and business objectives for the remainder of 2019. The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com.

  • GlobeNewswire

    Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer

    Celldex Therapeutics, Inc. (CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019. "Dr. Young’s notable career and strong track record of successful drug development make her an important addition to Celldex," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics.

  • GlobeNewswire

    Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma

    Celldex Therapeutics, Inc. (CLDX) today presented results from the CDX-3379 clinical program at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. To date, three studies of CDX-3379 have enrolled patients with head and neck squamous cell carcinoma (HNSCC), including the ongoing Phase 2 exploratory study of CDX-3379 in combination with Erbitux®  (cetuximab) in patients with cetuximab-resistant, advanced human papillomavirus (HPV) negative HNSCC who have previously been treated with an anti-PD1 checkpoint inhibitor. Emerging data from the Phase 2 study and earlier studies of CDX-3379 suggest that antitumor activity may be associated with somatic mutations in certain genes.

  • GlobeNewswire

    Celldex Provides Corporate Update and Reports First Quarter 2019 Results

    HAMPTON, N.J., May 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex.

  • GlobeNewswire

    Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019

    Celldex Therapeutics, Inc. (CLDX) presented interim data from the Company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer Research (AACR) Annual Meeting 2019. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.CDX-1140 is a fully human agonist anti-CD40 monoclonal antibody that was specifically designed to balance good systemic exposure and safety with potent biological activity, a profile which differentiates CDX-1140 from other CD40-activating antibodies.

  • GlobeNewswire

    Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019

    Celldex Therapeutics, Inc. (CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting 2019. “Our research and discovery efforts have yielded multiple promising candidates that address important needs in cancer immunotherapy and complement our pipeline,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “CDX-527 joins two powerful pathways in the immune system, PD-1 blockade and CD27 costimulation.

  • GlobeNewswire

    Celldex Provides Corporate Update and Reports Full Year 2018 Results

    HAMPTON, N.J., March 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.

  • GlobeNewswire

    Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • ACCESSWIRE

    Biotech Stocks To Watch

    HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...

  • GlobeNewswire

    Celldex Therapeutics Announces Reverse Stock Split

    Celldex Therapeutics, Inc. (CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 13, 2018, Celldex stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten and not more than one-for-fifteen.

  • ACCESSWIRE

    4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)

    CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.

  • ACCESSWIRE

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...

  • ACCESSWIRE

    These 4 Tech Stocks Could Set February Highs

    CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The future of the tech stock market will depend on two key factors: tech experts must continue to work to design and manufacture top-of-the-line products meant to elevate the human experience, and consumers must feel like these new pieces of tech will actually serve a significant purpose in their lives. ParcelPal Technology Inc (PTNYF) (PKG), Maxwell Technologies Inc (MXWL), Top Image Systems Ltd (TISA), and Celldex Therapeutics Inc (CLDX) represent four companies determined to utilize advanced technological solutions to improve the quality of life for consumers on a global scale. ParcelPal Technology Inc (PTNYF) (PKG), along with other companies in the space, is taking advantage of the fact that, as new technologies have been developed to meet the growing challenges in life, so too has the willingness of consumers to be persuadable, in terms of considering products they otherwise might not consider.

  • ACCESSWIRE

    Cannabis and Biotech Stocks that Could Explode

    HENDERSON, NV / ACCESSWIRE / January 29, 2019 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at ...

  • ACCESSWIRE

    Best Ways to Play Biotech Rally

    HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...

  • ACCESSWIRE

    A Biotech Play You Can't Afford To Miss

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...

  • GlobeNewswire

    Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting. MerTK is emerging as a promising target for cancer immunotherapy. Its expression in innate immune cells is believed to negatively regulate immune responses and genetic removal of MerTK renders mice resistant to some tumors.

  • GlobeNewswire

    Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Celldex Therapeutics, Inc. (CLDX) presented interim data today from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses. “We have completed four of the potential eight monotherapy dose levels and, to date, CDX-1140 has been well tolerated.

  • GlobeNewswire

    Celldex Provides Corporate Update and Reports Third Quarter 2018 Results

    HAMPTON, N.J., Nov. 07, 2018 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018. “We.